Automated chemiluminescence immunoassay for the detection of anti-nephrin autoantibodies

The authors aimed to develop a standardized automated chemiluminescence immunoassay (CLIA) for detecting anti-nephrin autoantibodies, which are important in autoimmune podocytopathies like minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). Their study demonstrated that the CLIA showed high concordance with existing methods and detected anti-nephrin IgG more frequently, suggesting its potential for clinical application in disease stratification and monitoring. The findings indicate that elevated anti-nephrin IgG levels are associated with worse clinical outcomes, including increased relapse risk in patients.